Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 213.95
(-1.86%)
INR 213.95
(-1.86%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 611.5 Million INR | 290.24% |
| 2022 | 156.7 Million INR | -80.22% |
| 2021 | 792.13 Million INR | -66.49% |
| 2020 | 2.36 Billion INR | 245.87% |
| 2019 | 683.44 Million INR | 4078.3% |
| 2018 | 16.35 Million INR | -28.41% |
| 2017 | 22.84 Million INR | -27.17% |
| 2016 | 31.37 Million INR | -94.37% |
| 2015 | 557.47 Million INR | 1223.51% |
| 2014 | 42.12 Million INR | -18.77% |
| 2013 | 51.85 Million INR | -93.59% |
| 2012 | 808.72 Million INR | 18.37% |
| 2011 | 683.21 Million INR | 984.47% |
| 2010 | 63 Million INR | 195.77% |
| 2009 | 21.3 Million INR | 23.94% |
| 2008 | 17.18 Million INR | 0.0% |
| 2007 | - INR | 0.0% |
| 2006 | - INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 923.8 Million INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 142.1 Million INR | 0.0% |
| 2023 Q4 | 611.5 Million INR | 0.0% |
| 2023 FY | 611.5 Million INR | 290.24% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 156.7 Million INR | -80.22% |
| 2022 Q4 | 156.7 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.92 Billion INR | 0.0% |
| 2021 Q2 | 1.55 Billion INR | 0.0% |
| 2021 Q4 | 792.13 Million INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 792.13 Million INR | -66.49% |
| 2020 FY | 2.36 Billion INR | 245.87% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q2 | 1.05 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 2.36 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 683.44 Million INR | 0.0% |
| 2019 FY | 683.44 Million INR | 4078.3% |
| 2019 Q2 | 91.1 Million INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 16.35 Million INR | 0.0% |
| 2018 Q2 | 10.9 Million INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 16.35 Million INR | -28.41% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 22.84 Million INR | -27.17% |
| 2017 Q4 | 22.84 Million INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 16.4 Million INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 31.37 Million INR | 0.0% |
| 2016 FY | 31.37 Million INR | -94.37% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 22.3 Million INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 557.47 Million INR | 1223.51% |
| 2015 Q2 | 191.7 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 557.47 Million INR | 0.0% |
| 2014 Q4 | 42.12 Million INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 42.12 Million INR | -18.77% |
| 2014 Q2 | 32.8 Million INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 575.6 Million INR | 0.0% |
| 2013 Q4 | 51.85 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 51.85 Million INR | -93.59% |
| 2012 Q4 | 808.72 Million INR | 0.0% |
| 2012 FY | 808.72 Million INR | 18.37% |
| 2011 FY | 683.21 Million INR | 984.47% |
| 2011 Q4 | 683.21 Million INR | 0.0% |
| 2010 FY | 63 Million INR | 195.77% |
| 2009 FY | 21.3 Million INR | 23.94% |
| 2008 FY | 17.18 Million INR | 0.0% |
| 2007 FY | - INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sigachi Industries Limited | 1.43 Billion INR | 57.253% |
| Ind-Swift Limited | 10.13 Billion INR | 93.969% |
| Bajaj HealthCare Limited | 3.32 Billion INR | 81.627% |
| Sakar Healthcare Limited | 793.51 Million INR | 22.938% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 99.08% |
| Innova Captab Limited | 2.45 Billion INR | 75.051% |
| Divi's Laboratories Limited | 30 Million INR | -1938.333% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -1229.868% |
| Morepen Laboratories Limited | 289.99 Million INR | -110.868% |
| Mankind Pharma Limited | 2.07 Billion INR | 70.484% |
| Sequent Scientific Limited | 4.87 Billion INR | 87.461% |
| Wanbury Limited | 1.16 Billion INR | 47.504% |
| Laurus Labs Limited | 25.77 Billion INR | 97.627% |
| Nectar Lifesciences Limited | 6.35 Billion INR | 90.378% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -256.601% |
| Alembic Limited | 91.5 Million INR | -568.306% |
| Hikal Limited | 8.17 Billion INR | 92.521% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | 88.084% |
| Neuland Laboratories Limited | 953.89 Million INR | 35.894% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | 83.808% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | 95.032% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -86.661% |
| Themis Medicare Limited | 957.92 Million INR | 36.164% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Zydus Lifesciences Limited | 8.04 Billion INR | 92.396% |
| Lupin Limited | 29.21 Billion INR | 97.907% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -3438.159% |
| Wockhardt Limited | 23.56 Billion INR | 97.404% |
| Vaishali Pharma Limited | 134.91 Million INR | -353.238% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | 78.563% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -583.928% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 98.331% |
| FDC Limited | 205.18 Million INR | -198.024% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 96.946% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -93.228% |
| Eris Lifesciences Limited | 27.81 Billion INR | 97.801% |
| Venus Remedies Limited | 413.3 Million INR | -47.955% |
| ZIM Laboratories Limited | 1.08 Billion INR | 43.809% |
| Bliss GVS Pharma Limited | 998.4 Million INR | 38.752% |
| Par Drugs and Chemicals Limited | - INR | -Infinity% |
| Caplin Point Laboratories Limited | 19.7 Million INR | -3004.061% |
| Shilpa Medicare Limited | 9.37 Billion INR | 93.477% |
| Albert David Limited | 33.24 Million INR | -1739.54% |
| Ajanta Pharma Limited | 352.8 Million INR | -73.328% |
| Hester Biosciences Limited | 2.44 Billion INR | 74.977% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | 5.918% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | 93.955% |
| Gufic Biosciences Limited | 3.32 Billion INR | 81.632% |
| Windlas Biotech Limited | 36.41 Million INR | -1579.484% |
| Procter & Gamble Health Limited | 95.6 Million INR | -539.644% |
| Aarey Drugs & Pharmaceuticals Limited | 313.52 Million INR | -95.041% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | 37.914% |
| Granules India Limited | 13.15 Billion INR | 95.35% |
| Aarti Drugs Limited | 5.64 Billion INR | 89.163% |
| Bal Pharma Limited | 1.39 Billion INR | 56.211% |
| Alkem Laboratories Limited | 14.18 Billion INR | 95.689% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 98.132% |
| Lincoln Pharmaceuticals Limited | 10.66 Million INR | -5632.096% |
| Medicamen Biotech Limited | 308.17 Million INR | -98.428% |
| Unichem Laboratories Limited | 2.47 Billion INR | 75.294% |
| Bafna Pharmaceuticals Limited | 243.89 Million INR | -150.725% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -13832.559% |
| Valiant Laboratories Limited | 767.08 Million INR | 20.283% |
| Orchid Pharma Limited | 1.35 Billion INR | 54.764% |
| Medico Remedies Limited | 80.5 Million INR | -659.59% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -267.895% |
| Ipca Laboratories Limited | 14.38 Billion INR | 95.749% |
| Brooks Laboratories Limited | 56.41 Million INR | -983.855% |
| Syncom Formulations (India) Limited | 724.86 Million INR | 15.64% |
| Piramal Enterprises Limited | 535.85 Billion INR | 99.886% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 98.48% |
| NATCO Pharma Limited | 3.71 Billion INR | 83.526% |
| Suven Life Sciences Limited | 7.09 Million INR | -8516.317% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 68.386% |
| Strides Pharma Science Limited | 25.16 Billion INR | 97.57% |
| Indoco Remedies Limited | 6.71 Billion INR | 90.9% |
| Alpa Laboratories Limited | 52.46 Million INR | -1065.539% |
| Lasa Supergenerics Limited | 220.76 Million INR | -176.995% |